States to Test Drug Pricing Policies

January 8, 2020

While Capitol Hill goes back on forth on drug pricing legislation, states are looking to test their own solutions this year.

According to a STAT report, Louisiana and Washington both are looking to deploy a subscription-based payment model for hepatitis C treatments. As part of the agreement, states would pay drugmakers a flat rate for an unlimited supply of the drugs.

Colorado is also taking a big leap on insulin prices after capping the cost of the drug at $100 for the state’s insured.

To read the full report on STAT, click here. (Paid subscription required)

Share This Story!